$0.84
+0.00 (+0.49%)
Open$0.84
Previous Close$0.84
Day High$0.84
Day Low$0.82
52W High$3.10
52W Low$0.68
Volume—
Avg Volume13.3K
Market Cap10.16M
P/E Ratio—
EPS$-0.30
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,794.0% upside
Current
$0.84
$0.84
Target
$24.31
$24.31
$15.00
$24.31 avg
$29.94
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 330.1K | 1.99M | 1.82M |
| Net Income | -4,044,462 | -271,887 | -219,394 |
| Profit Margin | -1,227.1% | -13.7% | -12.0% |
| EBITDA | -3,651,612 | -443,981 | -374,843 |
| Free Cash Flow | — | -242,138 | -341,295 |
| Rev Growth | — | +6.4% | +1.5% |
| Debt/Equity | 0.07 | 0.27 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |